The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.
Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug
Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart
Entresto's sales are still lower than expected; GSK CEO Witty to retire in 2017; tech assistants sometimes fail to account for women's health needs
It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.
With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.
Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck's Vytorin claims; Pacira settles off-label marketing case with the FDA
UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto
Negative news coverage of statins may lead people to stop taking their medication; second patient dies in Zafgen obesity drug trial; Gilead defends pricing
Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales
The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.
Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug
Lilly stops trial for experimental heart drug; Turing misses deadline to respond to lawmakers about price increase of Daraprim; the FDA expands indication for Opdivo
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic
Longer-term use of AstraZeneca's Brilinta approved; Google streamlines health-related searches; Zarxio's price is higher than expected
Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra
Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug
The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision
AstraZeneca inks cancer development deal; beta-blockers may increase survival in ovarian-cancer patients; OPDP finds corrective ads are ineffective
Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.
The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines
CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration
The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information
The drugmaker told investors that the actual-use trial failed to meet the primary objectives.
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe
The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands
- Healthline's traffic rises, putting it closer to WebMD and Everyday Health
- Five things for pharma marketers to know: Wednesday, August 17, 2016
- Five things for pharma marketers to know: Monday, August 22, 2016
- Five things for pharma marketers to know: Thursday, August 18, 2016
- Five things for pharma marketers to know: Tuesday, August 23, 2016